dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53

Genes Chromosomes and Cancer

Volumn 20, Issue 3, 1997, Pages 282-291

  Wang, Pauline ^a   Spielberger, Ricardo T ^a   Thangavelu, Maya ^a   Zhao, Nanding ^a   Davis, Elizabeth M ^a   Iannantuoni, Kiera ^a   Larson, Richard A ^a   Le Beau, Michelle M ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DNA; DOXORUBICIN; ETOPOSIDE; FLUOXYMESTERONE; HYDROXYUREA; INTERFERON; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; STEROID; TIOGUANINE; VINCRISTINE SULFATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CHILD; CHROMOSOME 17; CHROMOSOME 5; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 5; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DICENTRIC CHROMOSOME; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; MALE; MONOSOMY; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 5; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC;

EID: 0030783859     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199711)20:3<282::AID-GCC9>3.0.CO;2-Z     Document Type: Article

References (41)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1985) Proposed revised criteria for the acute myeloid leukemias: A report of the French-American-British Cooperative Group. Ann Intern Med 103:626-629.
3. Borgström GH, Vuopio P, de la Chapelle A (1982) Abnormalities of chromosome no. 17 in myeloproliferative disorders. Cancer Genet Cytogenet 5:123-135.
4. Boultwood J, Fidler C, Lewis S, Kelly S, Sheridan H, Littlewood TJ, Buckle VJ, Wainscoat JS (1994) Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: Delineation of the critical region on 5q and identification of a 5q-breakpoint. Genomics 19:425-432.
5. Caron de Fromentel C, Soussi T (1992) TP53 tumor suppressor gene: A model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15.
6. Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L (1995a) Physical mapping of the minimal region of loss in 5q-chromosome. Proc Natl Acad Sci USA 92:7406-7410.
7. Faitman J, Zhao L, Liang H, Claxton D, Chumakov I, Liang JC, Nowell PC, Nagarajan L (1995b) Anomalies of chromosome 5q in myelodysplasia and acute myelogenons leukemia: Evidence for multiple critical loci. Blood 86:164a.
8. Hagemeijer A, Sizoo W, Smit EME, Abiels J (1981) Translocation (5p;17q) in blast crisis of chronic myeloid leukemia. Cytogenet Cell Genet 30:205-210.
9. Hayani A, Suarez CR, Molnar Z, Le Beau MM, Godwin J (1994) Acute myeloid leukemia in a patient with Seckel syndrome. J Med Genet 31:148-149.
10. Heim S, Mitelman F (1995): Cancer Cytogenetics, 2nd Ed., New York: Wiley-Liss.
11. Hu G, Zhang W, Deisseroth AB (1992) P53 gene mutations in acute myelogenous leukaemia. Br J Haematol 81:489-494.
12. Huret JL, Schoenwald M, Gabarre J, Vaugier GL, Tanzer J (1991) Two additional cases of isochromosome 21q or translocation 21q21q in hematological malignancies. Acta Haematol 86:111-114.
13. ISCN (1995) An International System for Human Cytogcnetic Nomenclature. Mitelman F (ed). Basel: Karger, 1995.
14. Jonveaux Ph, Fenaux P, Quiquandon I, Pignon JM, Lai JL, Loucheux-Lefebvre MH, Goosens M, Bauters F, Berger R (1991) Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243-2247.
15. Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V (1989) Rearrangements of the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74:2318-2324.
16. Kerim S, Rege-Cambrin G, Scaravaglio P, Godio L, Saglio G, Aglietta M (1991) Trisomy 8 and an unbalanced t(5:17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. Cancer Genet Cytogenet 52:63-69.
17. Knapp RH, Dewald GW, Pierre RV (1985) Cytogenetic studies in 174 consecutive patients with preleukemia or myelodysplastic syndromes. Mayo Clin Proc 60:507-516.
18. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495.
19. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Wattel E, Fenaux P (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of p53 mutations. Leukemia 9:370-381.
20. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD (1986) Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4:325-345.
21. Le Beau MM, Espinosa R III, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA (1993) Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in myeloid leukemias. Proc Natl Acad Sci USA 90:5484-5488.
22. Lee EJ, Schiffer CA, Misawa S, Testa JR (1987) Clinical and cytogenetic features of familial erythroleukaemia. Br J Haematol 65:313-320.
23. Mamuris Z, Dumont J, Dutrillaux, Aurias A (1484) Chromosomal differences between acute nonlymphocytic leukemia in patients with prior solid tumors and prior hematologic malignancies. Cancer Genet Cytogenet 42:43-50.
24. Mamuris Z, Dumont J, Dutrillaux B, Aurias A (1990) Specific chromosomal mutagenesis observed in stimulated lymphocytes from patients with S-ANLL. Int J Cancer 46:563-568.
25. Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A (1990) Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75:180-189.
26. Michaud J, Brody LC, Steel G, Fontaine G, Martin LS, Valle D, Mitchell G (1992) Strand separating conformational polymorphism analysis: Efficiency of detection of point mutations in the human ornithine delta-aminotransferase gene. Genomics 13:389-394.
27. Misawa S, Hogge DE, Oguma N, Wiernik PH, Testa JR (1986) Detection of clonal karyotypic abnormalities in most patients with acute nonlymphocytic leukemia examined using short-term culture techniques. Cancer Genet Cytogenet 22:239-251.
28. Mitelman F (1994) Catalog of Chromosome Aberrations in Cancer, 5th Ed. New York: Wiley-Liss.
29. Murakami Y, Hayashi K, Hirohashi S, Sekiya T (1941) Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 51:5520-5525.
30. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708.
31. Ohyashiki K, Yoshida MA, Gibas JH, Ohyashiki JH, Katsunuma H, Ryan DH, Rowe DH, Rowe J, Sandberg AA (1986) Cytogenetic changes at 11q11, 11q23, and 17q11 in myelodysplastic syndrome. Cancer Genet Cytogenet 21:287-295.
32. Olopade OI, Thangavelu M, Larson RA, Mick R, Kowal-Vern A, Schumacher HR, Le Beau MM, Vardiman JW, Rowley JD (1992) Clinical, morphological, and cytogenetic characteristics of 26 patients with acute erythroblastic leukemia. Blood 80:2873-2882.
33. Pedersen-Bjergaard J, Janssen JWG, Lyons J, Philip P, Bartram CR (1988) Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res 48:1812-1817.
34. Rowley JD, Diaz MO, Espinosa R, Patel YD, van Melle E, Zieman S, Taillon-Miller P, Lichter P, Evans G, Kersey JH, Ward DC, Domer PH, Le Beau MM (1990) Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: Identification of 11q23 breakpoints with a yeast artificial chromosome. Proc Natl Acad Sci USA 87:9358-9362.
35. Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau MM, Cavenee W, Emanual B, Ponder B, Naylor S, Mitelman F, Louis D, Menon A, Newsham I, Dicker J, Kaelbling M, Henry I, v. Deimling A (1991) Report of the Committee on Chromosome and Gene Loss in Neoplasia (HGM11). Cytogenet Cell Genet 58:1080-1096.
36. Spurbeck JL, Carlson RO, Allen JE, Dewald GW (1988) Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet 32:59-66.
37. Testa JR, Misawa S, Oguma N, Van Sloten K, Wiernik PH (1985) Chromosomal alterations in acute leukemia patients studied with improved culture methods. Cancer Res 45:430-434.
38. Thangavelu M, Bitter MA, Larson RA, Davis EM, Rowley JD, Le Beau MM (1989) der(5)t(5;7)(q11.2;p11.2): A new recurring abnormality in malignant myeloid disorders. Cancer Genet Cytogenet 37:1-8.
39. Vandenberghe EA, Mecucci C, Delannoy A, Van den Berghe H (1990) Deletion of 5q by t(5;17) in therapy-related myelodysplastic syndrome. Cancer Genet Cytogenet 48:49-52.
40. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70:523-526.
41. Wilmoth D, Feder M, Finan J, Nowell P (1985) Preleukemia and leukemia with 12p- and 19q+ chromosome alterations following alkeran therapy. Cancer Genet Cytogenet 15:95-98.